TY - JOUR
T1 - Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma
T2 - an analysis of hospital data in the United States
AU - Maziarz, Richard T.
AU - Yang, Hongbo
AU - Liu, Qing
AU - Wang, Travis
AU - Zhao, Jing
AU - Lim, Stephen
AU - Lee, Soyon
AU - Dalal, Anand
AU - Bollu, Vamsi
N1 - Funding Information:
This work was supported by Novartis Pharmaceuticals Corporation. Medical writing was provided by Shelley Batts, PhD, an employee of Analysis Group, Inc. Support for this assistance was provided by Novartis Pharmaceuticals Corporation. Ethics approval and consent to participate : As the claims data used in this study were deidentified, no Institutional Review Board oversight was required.
Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - This study compared the real-world healthcare resource utilization (HRU), costs, adverse events (AEs), and AE treatments associated with the chimeric antigen receptor T-cell (CAR-T) therapies, tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel), for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Adults with DLBCL who received tisa-cel or axi-cel were identified in the Premier Healthcare Database (2017–2020). Non-CAR-T costs, HRU, and AE rates during the infusion and follow-up periods were compared between the tisa-cel and axi-cel cohorts. Of 119 patients, 33 received tisa-cel (86% as inpatient infusion) and 86 received axi-cel (100% inpatient). Tisa-cel was associated with significantly shorter mean inpatient length of stay than axi-cel during infusion (11.3 vs. 18.3 days) and follow-up ([monthly] 3.9 vs. 6.9 days). Non-CAR-T costs were significantly lower for tisa-cel compared with axi-cel during infusion ($27594.8 vs. $51378.3) and follow-up ([monthly] $28777.3 vs. $46575.7; both p<.05). Rates of AEs and AE treatments were similar.
AB - This study compared the real-world healthcare resource utilization (HRU), costs, adverse events (AEs), and AE treatments associated with the chimeric antigen receptor T-cell (CAR-T) therapies, tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel), for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Adults with DLBCL who received tisa-cel or axi-cel were identified in the Premier Healthcare Database (2017–2020). Non-CAR-T costs, HRU, and AE rates during the infusion and follow-up periods were compared between the tisa-cel and axi-cel cohorts. Of 119 patients, 33 received tisa-cel (86% as inpatient infusion) and 86 received axi-cel (100% inpatient). Tisa-cel was associated with significantly shorter mean inpatient length of stay than axi-cel during infusion (11.3 vs. 18.3 days) and follow-up ([monthly] 3.9 vs. 6.9 days). Non-CAR-T costs were significantly lower for tisa-cel compared with axi-cel during infusion ($27594.8 vs. $51378.3) and follow-up ([monthly] $28777.3 vs. $46575.7; both p<.05). Rates of AEs and AE treatments were similar.
KW - Adverse events
KW - axicabtagene ciloleucel
KW - diffuse large B-cell lymphoma
KW - healthcare costs
KW - healthcare resource utilization
KW - tisagenlecleucel
UR - http://www.scopus.com/inward/record.url?scp=85129158263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129158263&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2060503
DO - 10.1080/10428194.2022.2060503
M3 - Article
C2 - 35422192
AN - SCOPUS:85129158263
VL - 63
SP - 2052
EP - 2062
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 9
ER -